{'fraction_non_alphanumeric': 0.025856496444731737, 'fraction_numerical': 0.0, 'mean_word_length': 5.070588235294117, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Human Germline Gene Therapy: Scientific, Moral and Political Issues

Human germline gene therapy (HGLGT) was, until very recently, a taboo subject for serious policy discussion. In the past few years, however, a growing number of credible commentators-including, perhaps most prominently, the Nobel Prize-winning co-discoverer of DNA, James Watson-have raised the possibility of real-world applications of HGLGT. Like so many other biomedical advances before it-such as surrogate motherhood, in vitro fertilization, genetic screening of embryos, and now cloning-the public discourse on HGLGT has distinctly but subtly shifted from moral outrage and outright rejection to a more dispassionate debate on the pros and cons of the technology. It remains to be seen whether this transformation will continue along the path to experimentation, gradual acceptance, and finally widespread adoption, as it has for so many of the other biomedical advances over the past few decades. David Resnik, Holly Steinkraus, and Pamela Langer have provided a timely and helpful contribution to the public debate on HGLGT by providing in one concise volume a primer on the scientific, moral, and political issues associated with HGLGT. The book sets for itself a lofty task, not only to review the broad range of technical, ethical, policy, and legal issues involved with HGLGT, but to do so in a way that is accessible to the nonexpert and yet credible and insightful to experts. The premise for this ambitious undertaking is that public policy on HGLGT must take ac-